At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Anton Hagenbeek, MD, PhD, of Academic Medical Center, Amsterdam, The Netherlands, chairs a discussion with Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, and Franck Morschhauser, MD, PhD, of Centre Hospitalier Régional Universitaire de Lille, Lille, France, on new options and new challenges associated with the development of targeted therapies for non-Hodgkin lymphoma. There is a focus on clinical trial design, which must continue to adapt to the increasing number of emerging targeted therapies in order to establish if and how these new approaches can be incorporated into standard clinical care.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates